PRATH LOGO
Project image
place_project
bit_red  MUBODINA®

MUBODINA® is a human Recombinant Antibody able to bind the C5 component of Complement system; its most important characteristic is the ability to inhibit the activation of C5 into C5a and C5b, recognizing an epitope on the cleavage site for the C5 convertase on the alpha chain of the C5.

  Mubodina Image
Orphan designation (EU/3/08/571) was granted by the European Commission to ADIENNE S.r.l. (Italy) for MUBODINA® for the treatment of atypical Haemolytic Uraemic Syndrome (aHUS) associated with an inherited abnormality of the Complement system.
The Recombinant Human Antibody against Complement component C5 was isolated as a single chain variable fragment (scFv) from a large naive antibody library against human C5. The Recombinant Human Minibody against Complement component C5 is able to block the activation of C5 by both the classical and the alternative pathway of complement activation and to inhibit the haemolytic activity of C5 from pig, rabbit, rat, and mouse sera. To improve the bioavailability of the molecule in the blood and at inflammatory sites, the scFv was than fused to the Hinge-CH2-CH3 domains of human IgG1; this antibody was able to reduce complement-dependent damage in a rat model of arthritis (Marzari et al, Eur Jimmunol, 2002; Fischetti et al, Arthritis and Reum, 2007), was able to controls the development of thrombus formation induced by antibodies to B2-glycoprotein I in a rat model (Fischetti et al, Blood, 2005), and was able to prevent the development of ischemia-reperfusion injury in a rat model of heart transplant (Ferraresso et al, Transplantation, 2008).
     
graphic_footer_page